Viability On The Line: Defining Minimum Quality For CGT Raw Materials

The minimum-viable-product concept was born not in advanced therapy, but in the tech sector. It asks: What’s the smallest set of materials or features required to achieve the desired outcome? This principle can be a powerful guide when sourcing raw materials for gene therapy.

Executive Editor Jon O’Connell hosts this Cell & Gene Live event, exploring whether minimum viability can help gene therapy developers make smarter sourcing decisions — from research-grade production through clinical and commercial phases, where cost and quality can make or break a product.

Experts Yan Zhi, Ph.D., a director and product manager at CSL Behring, and Lawrence Thompson, Ph.D., an associate research fellow at Pfizer, will talk about sourcing and outsourcing decisions in the context of product quality, risk, and financial strategy. This is more than phase-appropriate supply chain strategies. Join us for an interactive discussion to unpack viability at the individual raw material level and the product candidate level.